Understand the source comparison
IGF-1 LR3 vs Native IGF-1: Research Application Comparison
Half-life 4–6 hours 20–30 hours IGF-1 LR3 for sustained activation studies; native IGF-1 for acute response models IGFBP binding >99% bound <10% bound IGF-1 LR3 eliminates IGFBP as confounding variable Dosing frequency Multiple daily or continuous infusion Onc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Half-life
- 4–6 hours
- 20–30 hours
- IGF-1 LR3 for sustained activation studies; native IGF-1 for acute response models
- IGFBP binding
- >99% bound
- <10% bound
- IGF-1 LR3 eliminates IGFBP as confounding variable
- Dosing frequency
- Multiple daily or continuous infusion
- Once daily or every 48 hours
- IGF-1 LR3 reduces dosing artifacts in multi-day protocols
- Tissue selectivity
- IGFBP-dependent spatial regulation
- Receptor density determines activation
- IGF-1 LR3 for uniform receptor activation; native for physiological tissue selectivity
- Cost per experiment
- Higher (frequent dosing)
- Lower (less frequent administration)
- Budget-constrained studies favor IGF-1 LR3 for equivalent activation days
- Professional Assessment
- Native IGF-1 replicates endogenous signaling patterns but requires complex dosing. IGF-1 LR3 simplifies protocols and isolates chronic receptor effects but eliminates physiological regulatory layers. Choose based on whether IGFBP regulation is the variable you're studying or a confound you need to remove.